Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods
- PMID: 480151
- DOI: 10.1007/BF01060020
Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods
Abstract
Previously published estimates of pharmacokinetic characteristics of quinidine can be shown to be dependent on whether the investigators have used analytical methods which are specific for quinidine. Areas under the plasma concentration-time curve and peak plasma concentrations after administration of the drug were higher and clearance values consequently lower in studies utilizing nonspecific assays unable to distinguish quinidine from its metabolities. The error introduced is larger after oral administration as a result of marked first-pass metabolism of quinidine. The absolute oral bioavailabilities from pharmaceutical preparations might therefore be estimated higher in studies with assays including metabolites in the determination. Although the pharmacodynamic response to quinidine is related to the plasma concentration, the therapeutic window of drug concentrations has been defined only using nonspecific assays. In light of the availability of newly developed specific assays, redefinition of the range of therapeutic plasma concentrations is opportune.
Similar articles
-
Pharmacokinetics of quinidine and three of its metabolites in man.J Pharmacokinet Biopharm. 1984 Feb;12(1):1-21. doi: 10.1007/BF01063608. J Pharmacokinet Biopharm. 1984. PMID: 6747817
-
Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution.Biopharm Drug Dispos. 1982 Oct-Dec;3(4):301-10. doi: 10.1002/bdd.2510030403. Biopharm Drug Dispos. 1982. PMID: 7159686 Clinical Trial.
-
Absolute quinidine bioavailability.Clin Pharmacol Ther. 1976 Sep;20(3):260-5. doi: 10.1002/cpt1976203260. Clin Pharmacol Ther. 1976. PMID: 954347
-
Pharmacokinetics in patients with cardiac failure.Clin Pharmacokinet. 1976 Nov-Dec;1(6):389-405. doi: 10.2165/00003088-197601060-00001. Clin Pharmacokinet. 1976. PMID: 799548 Review.
-
Clinical pharmacokinetics of quinidine.Clin Pharmacokinet. 1980 Mar-Apr;5(2):150-68. doi: 10.2165/00003088-198005020-00003. Clin Pharmacokinet. 1980. PMID: 6988137 Review.
Cited by
-
Clinical pharmacokinetics of antimalarial drugs.Clin Pharmacokinet. 1985 May-Jun;10(3):187-215. doi: 10.2165/00003088-198510030-00001. Clin Pharmacokinet. 1985. PMID: 3893840 Review.
-
Absorption of quinidine and dihydroquinidine in humans.Eur J Clin Pharmacol. 1981;21(3):195-9. doi: 10.1007/BF00627920. Eur J Clin Pharmacol. 1981. PMID: 7318878
-
Therapeutic drug monitoring: antiarrhythmic drugs.Br J Clin Pharmacol. 1998 Oct;46(4):307-19. doi: 10.1046/j.1365-2125.1998.t01-1-00768.x. Br J Clin Pharmacol. 1998. PMID: 9803978 Free PMC article. Review.
-
Drug metabolites in renal failure: pharmacokinetic and clinical implications.Clin Pharmacokinet. 1981 Sep-Oct;6(5):329-45. doi: 10.2165/00003088-198106050-00001. Clin Pharmacokinet. 1981. PMID: 7037261 Review. No abstract available.
-
Reliability of antiarrhythmic drug plasma concentration monitoring.Clin Pharmacokinet. 1983 Jan-Feb;8(1):63-82. doi: 10.2165/00003088-198308010-00004. Clin Pharmacokinet. 1983. PMID: 6404580 Review.